589 studies found for:    lenalidomide
Show Display Options
Rank Status Study
1 Active, not recruiting Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)
Condition: HIV-1 Infection
Interventions: Drug: Part A: lenalidomide dose escalation;   Drug: Part B: lenalidomide;   Drug: Part B: lenalidomide placebo
2 Completed
Has Results
A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes
Condition: Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
Interventions: Drug: Lenalidomide;   Drug: Recombinant human erythropoietin
3 Recruiting Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide, endoxan, prednisone;   Drug: lenalidomide, endoxan, prednisone
4 Unknown  Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Conditions: Follicular Lymphoma;   Marginal Zone B-Cell Lymphoma;   MALT Lymphoma;   Lymphoma of Mucosa-Associated Lymphoid Tissue;   Lymphoma, Small Lymphocytic;   Waldenstrom Macroglobulinemia;   Mantle-Cell Lymphoma
Interventions: Drug: lenalidomide-low dose dexamethasone plus rituximab;   Drug: Lenalidomide + Rituximab
5 Recruiting Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Condition: Relapsed Multiple Myeloma
Interventions: Drug: Lenalidomide 15mg;   Drug: Lenalidomide 25mg
6 Completed Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: lenalidomide
7 Completed
Has Results
Dasatinib in Combination With Revlimid (and Dexamethasone)
Condition: Multiple Myeloma
Interventions: Drug: Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg;   Drug: Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg;   Drug: Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg;   Drug: Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg;   Drug: Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg
8 Completed
Has Results
Study of Lenalidomide to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndromes (MDS) With a Del(5)(q31-33) Abnormality.
Condition: Myelodysplastic Syndromes
Intervention: Drug: Lenalidomide
9 Active, not recruiting Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
Condition: Advanced Cancers
Interventions: Drug: Lenalidomide;   Drug: Bevacizumab;   Drug: Sorafenib;   Drug: Temsirolimus;   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: 5-fluorouracil
10 Recruiting Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma
Condition: Myeloma
Interventions: Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: All-Trans Retinoic Acid (ATRA)
11 Recruiting Ipilimumab and Lenalidomide in Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Ipilimumab;   Drug: Lenalidomide
12 Active, not recruiting Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Intervention: Drug: lenalidomide
13 Recruiting A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma;   Adult Lymphocyte Predominant Hodgkin Lymphoma;   Adult Mixed Cellularity Hodgkin Lymphoma;   Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma;   Adult Nodular Sclerosis Hodgkin Lymphoma;   Recurrent Adult Hodgkin Lymphoma
Interventions: Drug: panobinostat;   Drug: lenalidomide
14 Completed
Has Results
Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality
Condition: Myelodysplastic Syndromes
Interventions: Drug: Lenalidomide 5 mg;   Drug: Lenalidomide 10 mg;   Drug: Placebo
15 Active, not recruiting A Study Being Conducted at Multiple Locations to Compare the Safety and Effectiveness of Three Different Treatment Regimens; 1) Lenalidomide, 2) Lenalidomide + Azacitidine, or 3) Azacitidine Alone in Newly Diagnosed Acute Myeloid Leukemia in Elderly Subjects ≥ 65 Years of Age
Conditions: Acute Myeloid Leukemia;   Acute Myelogenous Leukemia
Interventions: Drug: Azacitidine-single agent;   Drug: Lenalidomide - single agent;   Drug: Lenalidomide in combination with azacitidine
16 Active, not recruiting Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Relapsed Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: CC-5013
17 Completed
Has Results
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: CC-5013;   Drug: Dexamethasone
18 Completed
Has Results
A Phase II Study of CC-5013 in Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: CC-5013
19 Completed
Has Results
A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
Condition: Relapsed or Refractory Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: dexamethasone
20 Completed
Has Results
Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma
Intervention: Drug: Lenalidomide

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years